Simpson says trainer to blame for positive test

KINGSTON Tue Jan 7, 2014 6:46pm EST

1 of 2. Jamaica's Olympic sprinter Sherone Simpson (front L), who tested positive for doping at the Jamaican Championships in 2013, sits with her attorney Dianne Chai (front R), as they wait for the beginning of the hearing before the country's anti-doping commission in Kingston January 7, 2014.

Credit: Reuters/Gilbert Bellamy

Related Topics

Photo

Germany vs. Argentina

Highlights from the final.  Slideshow 

KINGSTON (Reuters) - Jamaican sprinter Sherone Simpson, who tested positive for a banned substance last year, told a disciplinary panel on Tuesday that she saw no "red flags" before taking a supplement supplied by her trainer.

Simpson, who faces a two-year ban if found guilty of a doping violation, testified in front of a three-member panel for over three hours and said a supplement provided by her Canadian trainer was responsible for her positive test.

Simpson was one of five Jamaicans to test positive at last June's national championships. Both she and former world 100 record holder Asafa Powell returned adverse findings for the banned substance oxilofrine.

The Olympic 4x100 relay silver medalist said she was not familiar with one of the five supplements given to her but that nothing on the bottle of Epiphany D1 appeared during her online search of the World Anti-Doping Agency's banned list.

"No alarm bell. No red flag," told the panel.

But a lawyer for the Jamaica Anti-Doping Commission said that there is no evidence to suggest oxilofrine is contained in Epiphany D1 and that Simpson was negligent not to have consulted a doctor.

The lawyer also said Simpson did not disclose that she was using Epiphany D1 along with three of the other four supplements provided to her by her trainer.

But Simpson, who said they were new additions to her regimen and that she could not recall their names at the times, insisted she was "not a cheat."

The hearing resumes on Wednesday.

(Editing by Frank Pingue)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.